Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL-II trial of ABT-450/r + ABT-267 + ABT-333 with or without ribavirin in treatment-experienced genotype 1b chronic hepatitis C
NL-OMON39091Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paritaprevir, ritonavir, glecaprevir, dasabuvir and ribavirin in chronic hepatitis C (CHC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: SVR12 non-inferiority of Arm 2 versus historical telaprevir plus pegylated interferon/ribavirin rate, SVR12 non-inferiority of Arm 1 versus historical telaprevir plus pegylated interferon/ribavirin rate and 1 more. Started May 2013; status: active, not recruiting.
02
Drugs
paritaprevirritonavirglecaprevirdasabuvirribavirin
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NL-OMON39091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39091.